Is CNS Pharmaceuticals, Inc. (CNSP) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 17.9% / 30% | 354.3% / 30% | 48.4% / 30% | N/A | ✗ NOT HALAL |
| DJIM | 17.9% / 33% | 354.3% / 33% | 48.4% / 33% | N/A | ✗ NOT HALAL |
| MSCI | 3.7% / 33% | 74.3% / 33% | 10.1% / 33% | N/A | ✗ NOT HALAL |
| S&P | 17.9% / 33% | 354.3% / 33% | 48.4% / 33% | N/A | ✗ NOT HALAL |
| FTSE | 3.7% / 33% | 74.3% / 33% | 10.1% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -197.1% | |
| Return on Assets (ROA) | -85.6% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$17M |
| Free Cash Flow | -$17M |
| Total Debt | $326,072 |
| Debt-to-Equity | 0.3 |
| Current Ratio | 5.8 |
| Total Assets | $9M |
Price & Trading
| Last Close | $2.56 |
| 50-Day MA | $3.93 |
| 200-Day MA | $6.86 |
| Avg Volume | 45K |
| Beta | 0.5 |
|
52-Week Range
$2.06
| |
About CNS Pharmaceuticals, Inc. (CNSP)
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, develops anti-cancer drug candidates for the treatment of brain and central nervous system (CNS) tumors. The company's drug candidates include TPI 287 and Berubicin, which are in Phase 2 clinical trial for the treatment of glioblastoma and other CNS malignancies. It has license agreement with Cortice Biosciences, Inc. The company was incorporated in 2017 and is headquartered in Houston, Texas.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is CNS Pharmaceuticals, Inc. (CNSP) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), CNS Pharmaceuticals, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is CNS Pharmaceuticals, Inc.'s debt ratio?
CNS Pharmaceuticals, Inc.'s debt ratio is 17.9% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 3.7%.
What are CNS Pharmaceuticals, Inc.'s key financial metrics?
CNS Pharmaceuticals, Inc. has a market capitalization of $2M, trailing P/E ratio of 0.0. Return on equity stands at -197.1%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.